Translation Research Core, China Medical University Hospital, China Medical University, Taichung, 40402, Taiwan.
Department of Nutrition, HungKuang University, Taichung, 43302, Taiwan.
Sci Rep. 2018 Oct 23;8(1):15658. doi: 10.1038/s41598-018-33927-5.
Programmed cell death-1 (PDCD1/PD-1) and its ligand programmed cell death 1 ligand 1 (CD274/PD-L1) have been reported to suppress anti-tumor T cell-mediated immune responses. However, the clinical significance of CD274 in colorectal cancer were still elusive. We aim to clarify the relationships between CD8+ intratumor-infiltrating lymphocytes (TILs) and CD274 as well as their prognostic values in stage II-III colon carcinoma. Tumor differentiation, perineural invasion (PNI), pN stage and DNA mismatch repair (MMR)-deficient were clearly correlated with CD8+ TILs counts within the tumor microenvironment (p < 0.0001). Furthermore, tumor differentiation and PNI were suggestively correlated with tumor CD274 expression (p = 0.02 and p = 0.0195). Tumor CD274 level was significantly correlated with higher CD8+ TILs (p < 0.0001) but was not associated with MMR-deficient status (p = 0.14). High tumor CD274 expression [hazard ratio (HR) = 2.16, 95% CI = 1.63-2.86, p < 0.0001] and CD8+ TILs [HR = 1.51, 95% CI = 1.19-1.91, p = 0.0007] were associated with improved disease-free survival and overall survival. Additionally, the subgroup of patients who had a high CD8+ TILs/tumor CD274 have better survival outcomes compared with other subgroups (71% vs 53%; p < 0.0001). Therefore, the CD8+ TILs counts and tumor CD274 may be prognostic factors to predict survival and therapeutic responses in stage II-III colon carcinoma patients.
程序性细胞死亡受体 1(PDCD1/PD-1)及其配体程序性细胞死亡受体 1 配体 1(CD274/PD-L1)已被报道抑制抗肿瘤 T 细胞介导的免疫反应。然而,CD274 在结直肠癌中的临床意义仍不清楚。我们旨在阐明肿瘤内浸润 CD8+T 淋巴细胞(TILs)与 CD274 之间的关系及其在 II-III 期结肠癌中的预后价值。肿瘤分化、神经周围侵犯(PNI)、pN 分期和错配修复(MMR)缺陷与肿瘤微环境中 CD8+TILs 计数明显相关(p<0.0001)。此外,肿瘤分化和 PNI 与肿瘤 CD274 表达呈提示性相关(p=0.02 和 p=0.0195)。肿瘤 CD274 水平与较高的 CD8+TILs 显著相关(p<0.0001),但与 MMR 缺陷状态无关(p=0.14)。高肿瘤 CD274 表达[危险比(HR)=2.16,95%置信区间(CI)=1.63-2.86,p<0.0001]和 CD8+TILs[HR=1.51,95%CI=1.19-1.91,p=0.0007]与无病生存和总生存改善相关。此外,高 CD8+TILs/肿瘤 CD274 亚组的生存结局优于其他亚组(71%比 53%;p<0.0001)。因此,CD8+TILs 计数和肿瘤 CD274 可能是预测 II-III 期结肠癌患者生存和治疗反应的预后因素。